FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 217 filers reported holding FATE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.68 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $7,606,000 | +35.1% | 130,000 | +36.8% | 2.10% | +30.0% |
| Q3 2021 | $5,631,000 | -18.9% | 95,000 | +18.8% | 1.62% | -15.3% |
| Q2 2021 | $6,943,000 | +110.5% | 80,000 | +100.0% | 1.91% | +102.9% |
| Q1 2021 | $3,298,000 | -2.9% | 40,000 | -52.9% | 0.94% | -9.3% |
| Q3 2020 | $3,397,000 | +41.4% | 85,000 | +21.4% | 1.04% | +44.5% |
| Q2 2020 | $2,402,000 | +13.8% | 70,000 | -26.3% | 0.72% | -22.6% |
| Q1 2020 | $2,110,000 | – | 95,000 | – | 0.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |